Transgenic Mouse Facility


The UC Irvine Transgenic Mouse Facility (TMF) is a core facility that provides services on a recharge basis for making, breeding, genotyping, importing, and preserving genetically-modified mice and embryonic stem cells. In addition to academic clients at UCI, we also service academic investigators at several other sister UC-campuses and numerous other universities throughout the USA as well as providing these services to commercial clients.

Got a question? Email the TMF - we're here to help!

"CRISPR" Cas9/gRNA genome editing services are available

In certain cases CRISPR Cas9/gRNA mediated gene editing can accelerate projects to modify the mouse genome. As of August 2016, the TMF has successfully completed 23 independent projects to modify the mouse genome via use of Cas9/gRNA. Most completed projects have involved introduction of point mutations, amino acid changes, loxP sites and exon deletions via Cas9/gRNA in combination with single-stranded oligodeoxynucleotide (ssODN) and homology dependent repair (HDR). This technology continues to evolve at a rapid pace and we routinely evaluate modifications of methods that may improve efficiency while using fewer animals.

Inquiries regarding gene targeting via Cas9 /gRNA should be directed to the TMF’s Managing Director, Jon Neumann

Of interest to TMF and Cancer Center users

Striking immune phenotypes in gene-targeted mice are driven by a copy-number variant originating from a commercially available C57BL/6 strain. (2016) Cell Reports 15.

Analysis of mammalian gene function through broad-based phenotypic screens across a consortium of mouse clinics. Hrabe de Angelis et al, (2015) Nature Genetics 47, p969.

CRISPR-mediated direct mutation of cancer genes in the mouse liver, Xue W, et al., Nature (2014) doi:10.1038/nature13589

Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype, Yin H, et al., Nature Biotechnology (2014) doi:10.1038/nbt.2884

'Humanized' Mouse Detects Deadly Drug Side Effects, J. Cohen, Science (2014) 344, p244

The APL Paradigm and the "Co-Clinical Trial" Project. Nardella, et al., Cancer Discovery (2011) 1, p108. DOI:10.1158/2159-8290.CD-11-0061

How can we assist you ?

The TMF is a Shared Resource funded in part by the Chao Family Comprehensive Cancer Center Support Grant (P30CA062203) from the National Cancer Institute, by Strategic Partnerships with various UCI Offices and Schools, and by established chargeback systems.
Chao Family Comprehensive Cancer Center

News & Announcements

View More